Medivolve Inc. (MEDV.NE)

Medivolve’s Q3 earnings came as a shock to investors and traders alike. This tiny little micro cap basically earned its total market cap value in the span of 3 months because of changes in government support regarding Covid testing and the upcoming OSHA mandate again regarding that Employers ensure that all their employees are vaccinated or else weekly testing would have to be carried out! These changes enabled Medivolve to transition from a cash pay business model to directly receive payment from insurance companies covering the immediate costs for patients needing Covid testing. This has given MEDV.NE a meteoric rise in revenue and growth. We’re only about a month away from Q4 earnings which should be even better than Q3’s 25.3 million intake. Investors could see 2-3x gains on their investment after Q4 results have been reported. For me it’s a good way to earn back some of the losses from this market sell off. GLTA!

Los Angeles Times just reported...that in December, neighborhood pharmacies sold out of rapid antigen tests. Also Getting an appointment for the more sensitive and definitive PCR test took days, and results even longer and testing received all time high demand.

This Q's Rev will easily surpass MEDVs entire MC and profit will most likely be around 15 mil or 22 mill if the 7 mil owed is paid.

That puts this P/E ratio at an absolutely absurd level and wouldn't even include the overwhelming demand for MEDVs products lately. Adjusted EBITDA will will be interesting but we can easily assume this stock doubles on earnings and heads to more of a fair value of at least half of what it's worth which would be a nice bagger between mid FEB-MAY.

Anyone selling at a 30 mil MC right now will be weeping come earnings.

This is going to pay off huge, for investors Come Q4. Q3 showed us just how much money Medivolve was generating since transitioning from a cash pay business model to insurance Reimbursements increasing daily gross revenue and revenue per patient compared to the legacy cash- based business model used since the company’s inception. Medivolve has boosted testing services revenue by automating claim submission to over 8,700 insurance carriers; this, combined with access to respective government programs has led to a population coverage of 99.7% of individuals who are either uninsured or undocumented and eligible for Covid-19 testing at no cost to patient. MEDV.NE Announced an unprecedented 25.3 million dollar Q3 revenue intake on November 15 2021. Much of their revenue intake came from the last month and half due to changes in legislation, more funding and a tougher stance on and push to have everyone vaccinated. The OSHA rule requires employers with 100 or more workers to make them get vaccinated or be tested regularly, potentially at their own expense. Although the rule had partially taken effect, OSHA had said it wouldn’t issue citations until at least Feb. 9 to employers who were trying in good faith to comply with the testing requirements. Biden said the health-care ruling “will save lives: the lives of patients who seek care in medical facilities, as well as the lives of doctors, nurses, and others who work there. He added: “It will cover 10.4 million health care workers at 76,000 medical facilities. We will enforce it.”
As for Q4 earnings which I would think should be in February, it’s been guesstimated to be quite a bit more than Q3 was, with yearly revenue intake to be in excessive of $200-$300 million. With a market cap of only $20-30 million US, $30-40 million CDN, Medivolve’s market value and share price should move up sharply. Goes without saying that this is one hell of a good investment opportunity!$$, GLTA!